Hdl Handle:
Transparent development of the WHO rapid advice guidelines.
Schünemann, Holger J; Hill, Suzanne R; Kakad, Meetali; Vist, Gunn Elisabeth; Bellamy, Richard; Stockman, Lauren; Wisløff, Torbjørn Fosen; Del Mar, Chris; Hayden, Frederick; Uyeki, Timothy M; Farrar, Jeremy; Yazdanpanah, Yazdan; Zucker, Howard; Beigel, John; Chotpitayasunondh, Tawee; Hien, Tran Tinh; Ozbay, Bülent; Sugaya, Norio; Oxman, Andrew David
PLoS medicine 2007, 4 (5):e119

Full metadata record

DC FieldValue Language
dc.contributor.authorSchünemann, Holger J-
dc.contributor.authorHill, Suzanne R-
dc.contributor.authorKakad, Meetali-
dc.contributor.authorVist, Gunn Elisabeth-
dc.contributor.authorBellamy, Richard-
dc.contributor.authorStockman, Lauren-
dc.contributor.authorWisløff, Torbjørn Fosen-
dc.contributor.authorDel Mar, Chris-
dc.contributor.authorHayden, Frederick-
dc.contributor.authorUyeki, Timothy M-
dc.contributor.authorFarrar, Jeremy-
dc.contributor.authorYazdanpanah, Yazdan-
dc.contributor.authorZucker, Howard-
dc.contributor.authorBeigel, John-
dc.contributor.authorChotpitayasunondh, Tawee-
dc.contributor.authorHien, Tran Tinh-
dc.contributor.authorOzbay, Bülent-
dc.contributor.authorSugaya, Norio-
dc.contributor.authorOxman, Andrew David-
dc.identifier.citationPLoS medicine 2007, 4 (5):e119en
dc.description.abstractEmerging health problems require rapid advice. We describe the development and pilot testing of a systematic, transparent approach used by the World Health Organization (WHO) to develop rapid advice guidelines in response to requests from member states confronted with uncertainty about the pharmacological management of avian influenza A (H5N1) virus infection. We first searched for systematic reviews of randomized trials of treatment and prevention of seasonal influenza and for non-trial evidence on H5N1 infection, including case reports and animal and in vitro studies. A panel of clinical experts, clinicians with experience in treating patients with H5N1, influenza researchers, and methodologists was convened for a two-day meeting. Panel members reviewed the evidence prior to the meeting and agreed on the process. It took one month to put together a team to prepare the evidence profiles (i.e., summaries of the evidence on important clinical and policy questions), and it took the team only five weeks to prepare and revise the evidence profiles and to prepare draft guidelines prior to the panel meeting. A draft manuscript for publication was prepared within 10 days following the panel meeting. Strengths of the process include its transparency and the short amount of time used to prepare these WHO guidelines. The process could be improved by shortening the time required to commission evidence profiles. Further development is needed to facilitate stakeholder involvement, and evaluate and ensure the guideline's usefulness.en
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Helsetjeneste- og helseadministrasjonsforskning: 806en
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801en
dc.subject.meshAdvisory Committeesen
dc.subject.meshInfluenza A Virus, H5N1 Subtypeen
dc.subject.meshInfluenza, Humanen
dc.subject.meshOutcome Assessment (Health Care)en
dc.subject.meshPractice Guidelines as Topicen
dc.subject.meshProgram Developmenten
dc.subject.meshWorld Health Organizationen
dc.titleTransparent development of the WHO rapid advice guidelines.en
dc.typeJournal articleen
dc.typepeer revieweden
dc.contributor.departmentItalian National Cancer Institute Regina Elena, Department of Epidemiology, Rome, Italy. Schuneh@mcmaster.caen
dc.identifier.journalPLoS medicineen
All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.